THU0535 Quality of Life in Patients with Gout in South Western Sydney
Authors: S.-N. Luong, V. Thakkar, G. Hassett, H. Mannan, K. Pile
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is the most common type of inflammatory arthritis in men, with an Australian population prevalence of 0.39% (1, 2). Due to ageing and rising obesity, the global burden of gout is increasing. Global disability adjusted life years (DALYs) for gout rose from 76 000 in 1990 to 114 000 in 2010 (2). Patients with severe gout are known to have low health-related quality of life (HRQOL), especially in regards to physical function (3). <h3>Objectives</h3> To determine HRQOL in gout patients of South Western Sydney, and the utility of the Gout Impact Scale (GIS). To compare GIS in patients with acute versus non-acute gout, and high frequency of gout attacks versus low frequency of gout attacks. To compare Short Form 36 version 2 (SF36v2) in our gout cohort with normals and other chronic diseases. <h3>Methods</h3> Postal cross-sectional survey study of adult patients diagnosed with gout recruited from 3 public hospitals and a private clinic. SPSS software facilitated analysis. <h3>Results</h3> 133/184 patients recruited with a 72.3% response rate. The overall impact of gout on their life was 5.9/10, higher in acute gout vs non-acute gout, mean 6.8 vs 5.2, p&lt;0.02. Of patients with gout attack in the last 3 months, the severity of pain was 6.8/10. Patients with more frequent attacks of gout had higher overall severity of gout than those with less frequent attacks, mean 7.5 vs 5.2, p&lt;0.002. Patients with acute gout had higher mean scores for gout concern overall (GCO), gout medication side effects (GMSE), unmet gout treatment need (UGTN), well being during attack (WBDA) and gout concern during attack (GCDA), compared to non-acute gout, p&lt;0.02. There was a moderate correlation between GCDA and GCO (τ<sub>b</sub> =0.566, p&lt;0.0001) and GCDA and WBDA (τ<sub>b</sub>=0.508, p&lt;0.0001) Patients with more frequent attacks had higher mean scores for GCO, GMSE, UGTN, WBDA and GCDA, compared to those with less frequent attacks, p&lt;0.002. Gout patients scored significantly lower in all 8 domains of SF36v2 compared to Australian normative data and diabetics. There was a moderate correlation between WBDA and the mental component summary of SF36v2 (τ<sub>b</sub> =-0.406, p&lt;0.0001). <h3>Conclusions</h3> Results of the Gout Impact Scale made sense with greater impact of gout in patients with acute gout or more frequent attacks in all 5 scales, suggesting it is a robust instrument in the diverse gout population. The impact of gout was not confined to just physical domains, but had a significant negative impact on psychological health. <h3>References</h3> Becker MA et al. Quality of life and disability in patients with treatment failure gout. J Rheumatol. 2009;36(5):1041–8. Smith E et al. The global burden of gout estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(8):1470–6. Hirsh JD et al. Gout disease specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010;1:1–8. Marin T, Taylor A &amp; Gill T. A population profile of quality of life in south australia population norms for 2008 using the SF36 version 2. Population Research and Outcome Studies Unit. South Australian Department of Health, Adelaide. September 2009. <h3>Disclosure of Interest</h3> None declared